Pharming Group melaporkan hasil keuangan kuartal ketiga 2026; pertumbuhan pendapatan yang kuat, ekspansi Joenja APDS dan data topline CVID pada bulan November
Pharming Group melaporkan kenaikan pendapatan total kuartal ketiga 2026 sebesar 21% menjadi $117,6 juta, melampaui estimasi pasar berkat tingginya permintaan RUCONEST. Perusahaan bioteknologi ini juga menyoroti perluasan lini produk yang sedang berjalan serta rilis data topline yang akan datang.
Pharming Group delivered robust financial results for the third quarter of 2026, posting total revenues of $117.6 million, which represents a 21% year-over-year growth and surpasses consensus analyst expectations. The growth was primarily driven by flagship product RUCONEST, which generated $93.8 million in revenue, reflecting stable demand and seasonal inventory adjustments. Management also provided updates on its broader clinical portfolio, including the Joenja APDS expansion and anticipated CVID topline data expected in November. These operational milestones validate the company's commercial strategy and strengthen its balance sheet for ongoing clinical trials. Investors responded favorably to the resilient top-line growth and clear regulatory roadmap for upcoming product indications. The positive performance reinforces confidence in Pharming Group's ability to scale its rare disease treatment portfolio.
Penafian analisis AI
Analisis dampak aset dibuat oleh AI dan hanya untuk tujuan informasi. Ini bukan nasihat keuangan. Selalu lakukan riset sendiri sebelum mengambil keputusan investasi.
Diskusi